Patient Clinical Trials

See All Mercy Clinical Trials ›

Currently Displaying: Active Clinical Trials

Hide
Trial Status

Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Topic of Study: Gynecologic Cancer
Principal Investigator: Teresa Diaz-Montes, M.D., 410-332-9250, Armando Sardi, M.D., 410-332-9294
Research Coordinator: Michelle Sittig, RN, 410-332-9294
For More Information: 410-332-9329 or 410-332-9294
Coordinated Through: The Gynecologic Oncology Center at Mercy and Surgical Oncology at Mercy

The purpose of this phase II trial is to determine the toxicity and post-operative complications related to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as an initial treatment option for patients with ovarian, fallopian tube, or primary peritoneal cancers and its impact on quality of life.  Subjects will be randomized to one of two treatment groups: CRS with HIPEC followed by combination chemotherapy, carboplatin and paclitaxel, or CRS only followed by combination chemotherapy carboplatin and paclitaxel.

Protocol Title and ClinicalTrials ID#: A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy with carboplatin and paclitaxel as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer. NCT02124421

Development of Patient-derived Tumorgrafts as a Model for the Discovery of Biomarkers and Therapeutic Approaches for Gynecological Tumors

Topic of Study: Gynecologic Cancer
Principal Investigator: Teresa Diaz-Montes, M.D., 410-332-9250
Research Coordinator: Michelle Sittig, RN or Angie Gahres, BSN, RN at 410-332-9294
For More Information: 410-332-9294
Coordinated Through: The Gynecologic Oncology Center at Mercy and Johns Hopkins University, Oncology - Cancer Prevention and Control

The objective of this study is to collect patient specimens prospectively (tumor, blood, vaginal swab, and urine sample) from benign, high risk, and malignant surgeries in order to develop diagnostic biomarkers and targeted anticancer agents for gynecologic tumors. http://lifegenedna.com/

Proclaim

Topic of Study: Chemotherapy Induced Thrombocyopenia
Sponsor: Amgen
Principal Investigator: Sandy Kotiah, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200; Alexandra Cline, RN, 410-951-7956
Coordinated Through: Institutional Research

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Non Small Cell Lung Cancer, Ovarian Cancer or Breast Cancer. (Clinicaltrials.gov ID#: NCT03937154)